MGMT and glioblastoma: The CheckMate 498 trial found that nivolumab (PD-1 monoclonal antibody) did not improve OS in MGMT promoter-methylation-negative GBM patients, while CheckMate 548 showed no improvement in PFS in MGMT promoter-methylation-positive GBM patients, although OS is still under evaluation (67, 68).